Spinal cord stimulation market seen reaching $5.8B by 2033

By AI, Created 9:38 AM UTC, May 20, 2026, /AGP/ – Persistent Market Research projects the global spinal cord stimulation system market will grow from about $3.4 billion in 2026 to $5.8 billion by 2033, fueled by chronic pain cases, non-opioid treatment demand and device innovation. North America is expected to lead, while Asia Pacific is forecast to grow fastest.

Why it matters: - The spinal cord stimulation system market is growing as healthcare providers look for non-opioid options for chronic pain. - Rising demand could expand access to neuromodulation therapies for patients who do not respond well to standard drug treatments. - The market opportunity also reflects broader pressure to reduce reliance on opioid-based pain care.

What happened: - Persistence Market Research projected the global spinal cord stimulation system market at about US$3.4 billion in 2026. - The market is expected to reach US$5.8 billion by 2033. - The forecast implies a 7.9% compound annual growth rate from 2026 to 2033. - The report tied the outlook to rising chronic pain conditions, technology upgrades and a shift toward non-opioid pain therapies. - The release was dated April 30, 2026 and issued from London. - A free sample is available here. - Custom research requests are available here.

The details: - Chronic pain categories driving demand include neuropathic pain, degenerative spinal disorders and failed back surgery syndrome. - Aging populations and more spinal surgeries are adding to chronic post-surgical pain cases. - Rechargeable systems are expected to account for 60% of revenue share by 2026. - Rechargeable devices are favored for longer battery life, fewer replacement surgeries and better patient compliance. - High-frequency and burst stimulation are cited as advanced modes that can improve pain relief outcomes. - Closed-loop feedback systems are gaining traction because they can adjust stimulation in real time based on patient feedback. - Wireless connectivity and remote programming are becoming more common in spinal cord stimulation devices. - North America is projected to hold 45% of market share by 2026. - The U.S. market is described as having broad neuromodulation adoption, with Medtronic’s Intellis rechargeable neurostimulator cited as an example. - Asia Pacific is expected to be the fastest-growing region, helped by higher healthcare investment, aging demographics and greater awareness of advanced pain management. - Europe is also expanding, with Germany, the U.K. and France highlighted. - Failed back surgery syndrome is expected to represent more than 50% of revenue share by 2026. - Complex regional pain syndrome is projected to be the fastest-growing application segment. - The market is segmented by product type into conventional, radiofrequency, rechargeable and non-rechargeable systems. - The application segment also includes failed back syndrome, complex regional pain syndrome, degenerative disk disease, unsuccessful disk surgery and arachnoiditis. - End users include hospitals, physiotherapy centers, ambulatory surgical centers and clinics. - Regional segmentation includes North America, Europe, East Asia, South Asia & Oceania, Latin America, and Middle East & Africa. - Major players listed in the market include Medtronic, Abbott Laboratories, Boston Scientific and Nevro Corp. - Boston Scientific launched its Precision Plus™ SCS System in 2025.

Between the lines: - The market forecast suggests chronic pain treatment is continuing to move toward device-based therapies instead of long-term medication alone. - Reimbursement remains a major gatekeeper, because eligibility rules and authorization delays can slow adoption even in developed markets. - High device costs and limited insurance coverage continue to restrict access in developing countries. - The strongest growth opportunities appear to be outside traditional post-surgical pain use cases, especially non-surgical back pain and peripheral neuropathies such as diabetic neuropathy. - Rising diabetes rates could broaden the addressable patient pool for spinal cord stimulation.

What’s next: - Device makers are likely to keep investing in rechargeable platforms, closed-loop systems and remote programming features. - Clinical evidence for non-surgical back pain and neuropathy indications may help expand reimbursement and adoption. - Competitive pressure is likely to remain high as major manufacturers expand product portfolios and pursue new launches. - The market’s regional growth path will likely depend on healthcare spending, reimbursement policy and specialty pain clinic capacity.